Status and phase
Conditions
Treatments
About
This is a Phase 2, multicenter, open-label, 3-arm, randomized, parallel group study to evaluate the efficacy and safety of TTX-030 with or without budigalimab in combination with chemotherapy (gemcitabine + nab-paclitaxel) in subjects with metastatic PDAC who did not have prior treatment for metastatic disease and are eligible to receive gemcitabine and nab-paclitaxel chemotherapy as SOC.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Abbreviated Inclusion Criteria:
Abbreviated Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
194 participants in 3 patient groups
Loading...
Central trial contact
Trishula Therapeutics, Inc.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal